Signaturefd LLC Boosts Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Signaturefd LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,248 shares of the company’s stock after purchasing an additional 50 shares during the quarter. Signaturefd LLC’s holdings in IDEXX Laboratories were worth $693,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Gotham Asset Management LLC raised its stake in shares of IDEXX Laboratories by 79.9% during the third quarter. Gotham Asset Management LLC now owns 17,427 shares of the company’s stock valued at $7,620,000 after purchasing an additional 7,741 shares during the period. NewEdge Wealth LLC raised its stake in shares of IDEXX Laboratories by 30.4% during the third quarter. NewEdge Wealth LLC now owns 639 shares of the company’s stock valued at $279,000 after purchasing an additional 149 shares during the period. Assenagon Asset Management S.A. grew its position in shares of IDEXX Laboratories by 25.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 43,593 shares of the company’s stock worth $24,196,000 after buying an additional 8,831 shares in the last quarter. Carderock Capital Management Inc. grew its position in shares of IDEXX Laboratories by 35.7% during the fourth quarter. Carderock Capital Management Inc. now owns 16,416 shares of the company’s stock worth $9,112,000 after buying an additional 4,315 shares in the last quarter. Finally, Mitchell Capital Management Co. grew its position in shares of IDEXX Laboratories by 1.3% during the third quarter. Mitchell Capital Management Co. now owns 6,372 shares of the company’s stock worth $2,786,000 after buying an additional 79 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDEXX Laboratories stock opened at $493.80 on Wednesday. The company has a current ratio of 1.57, a quick ratio of 1.17 and a debt-to-equity ratio of 0.42. The company’s 50-day moving average price is $535.07 and its two-hundred day moving average price is $510.61. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The stock has a market cap of $41.01 billion, a PE ratio of 49.04, a price-to-earnings-growth ratio of 3.69 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, February 5th. The company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. During the same period in the previous year, the business earned $2.05 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 8.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on IDXX shares. JPMorgan Chase & Co. raised their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. The Goldman Sachs Group lifted their price objective on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Barclays lifted their price objective on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the stock an “overweight” rating in a report on Tuesday, February 6th. Piper Sandler downgraded shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective for the company. in a report on Tuesday, January 30th. Finally, William Blair reissued an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average target price of $591.50.

Insiders Place Their Bets

In other IDEXX Laboratories news, CFO Brian P. Mckeon sold 23,326 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the sale, the chief financial officer now owns 29,718 shares in the company, valued at approximately $16,939,557.18. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the completion of the sale, the chief executive officer now directly owns 79,247 shares in the company, valued at $45,377,624.67. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the sale, the chief financial officer now owns 29,718 shares of the company’s stock, valued at $16,939,557.18. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,524 shares of company stock worth $24,871,960. 2.18% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.